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Introduction
Soft-tissue tumors are not uncommon and most are
benign. In the USA, the annual incidence of soft-tissue
tumors is approximately 3 cases per 1,000 people,
approximately 1 in 150 of which are malignant.1 Soft-
tissue malignancy accounts for 0.64% of all malignant
tumors in Taiwan.2 These tumors include soft-tissue
sarcomas, the outcomes of which vary with prompt
management. As with small tumors, prognosis is better
for low-grade than for high-grade sarcoma.3,4
Several imaging modalities are used to assess soft-
tissue tumors, including plain radiography, nuclear
medicine study, high-resolution ultrasonography (US),
computed tomography (CT), magnetic resonance im-
aging, angiography, and positron emission tomography.
However, none of them reliably distinguish benign
from malignant lesions,5,6 including high-resolution
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US, despite its high sensitivity in detecting tumors.7,8
Power Doppler US (PDUS) or color Doppler US
(CDUS) with spectral analysis can show vascular irre-
gularities in malignant tumors, but the reported criteria
for malignancy vary widely,9 and some investigators have
questioned their usefulness in distinguishing benign
from malignant lesions.10,11 PDUS is generally supe-
rior to CDUS, especially in situations of low-velocity
blood flow.12 Three-dimensional (3D) US has shown
promising results in the obstetric, gynecologic, pros-
tate, and cardiovascular fields.13–15 Three-dimensional
PDUS (3D-PDUS) is used in gynecologic and neck
lymph node differentiation,16,17 and in adnexa masses
to quantify blood flow and vascularization.18
Contrast medium injection US may provide more
detailed information on tumor vascularity,19,20 and it
has greatly increased sensitivity to slow flow, compared
with Doppler US. A liver study showed that contrast-
enhanced US improves the accuracy and confidence
of diagnosis of focal liver lesions and reduces the need
for further studies.21 We previously found that when
applying 3D-PDUS in soft-tissue neoplasm, there
seemed to be no significant difference in the differen-
tial diagnosis between benign and malignant.22 The
purpose of this study was to evaluate the ability of
3D-PDUS to differentiate soft-tissue masses from
blood flow and vascularization of the neoplasm, with
and without contrast medium injection.
Methods
A total of 25 patients (13 females, 12 males; mean
age, 44.1 years; age range, 12–77 years) were enrolled
in this study. They were consecutively referred from
the orthopedics and oncology departments at Taipei
Veterans General Hospital to radiology for assessment.
This study was approved by the institutional review
board of Taipei Veterans General Hospital, and each
patient provided written informed consent before
examination.
The procedures were performed using a GE-Kretz
Voluson 730 Expert 3D-PDUS machine (GE Medical
Systems/Kretztechnik, Zipf, Austria), equipped with an
RSP 6–12 MHz linear-array or RAB 2–5 MHz curve
linear-array mechanically-driven transducer. Volume
data acquisition was performed using linear and con-
vex 3D probes. Tumor size influenced the duration of
the scanning procedure. The scanning angle depended
on the size and color of the tumor. Instrument set-
tings for pulse repetition frequency, signal power, wall
motion filter, persistence and color gain were adjusted
for optimal signal quality in each nodule and condition
before and after contrast medium injection. The con-
trast medium used was Levovist (Schering AG, Berlin,
Germany), prepared with 300 mg/mL medium in a
total of 2 g solution and injected through the antecu-
bital vein manually via bolus injection within 10 sec-
onds. All patients were scanned by the same senior
sonologist (H.J. Chiou), an ultrasound radiologist with
more than 15 years’ experience. The volume data were
stored on the hard disk of the US machine with a CD
backup. The tumor was traced slice by slice for > 12
slices by the same physician on the US machine. To
avoid bias, the 36 nodules, all of which had 3D-PDUS
data stored in the ultrasound machine, were traced
manually by 2 senior sonographers, who had 7 years
and 12 years of ultrasound scanning experience, respec-
tively. The vascular index (VI) or vessels in the tumor,
flow index (FI) or intensity of flow at the time of the
3D sweep, and vascular-flow index (VFI) or blood flow
and vascularization, were then automatically calculated
after the tumor was completely traced. VI was calcu-
lated as the number of color voxels (total voxels minus
background voxels), FI was defined as the number of
weighted color voxels (color voxels minus border vox-
els), and VFI was calculated as the number of weighted
total voxels (total voxels minus background voxels).18
All tumors were verified by US-guided biopsy or sur-
gical pathology.
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA)
for Windows was used for statistical analysis, including
the interobserver reliability test (paired t test to test
the agreement commitment) and nonparametric t test
(Mann-Whitney test).
Results
There were 8 benign and 17 malignant tumors. The
benign tumors included neurogenic tumors in 3 pa-
tients, inflammatory processes in 3 patients, leiomy-
oma in 1 patient and tumoral calcinosis in 1 patient.
The malignant tumors included osteogenic sarcoma
in 7 patients (1 post chemotherapy), liposarcoma in 
4 patients, lymphoma in 2 patients, carcinoma metas-
tasis in 2 patients, malignant fibrous histiocytoma in 
1 patient and breast carcinoma in 1 patient.
Mean tumor volume was 36.5 mL (range, 2.4–
124 mL) in benign tumors, and 319.4 mL (range,
9.9–1,179.6 mL) in malignant tumors. The VI, FI
and VFI before contrast medium injection are shown
in Table 1 (see also Figures 1A and 2A), while those
after contrast medium injection are shown in Table 2
(see also Figures 1B and 2B). There were no signifi-
cant differences between benign and malignant tumors
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in tumor volume, VI, FI and VFI before and after
echo-contrast medium injection (p > 0.05). Agreement
between the 2 sonographers showed high reliability,
with an intraclass correlation of 0.999 (Figure 3).
The differences in VI, FI and VFI between before and
after contrast medium injection are shown in Table 3.
Malignant tumors had significantly higher differences
for VI (p=0.03), FI (p=0.01) and VFI (p=0.03) under
self-differentiation. The cutoff values for VI, FI and
VFI under self-differentiation after and before echo-
contrast injection were 13.6, 6.0, and 5.1, respectively,
with a sensitivity of 88.9% and a specificity of 57%.
Discussion
The 3D volume was generated from stacked 2D
images by automatic mechanical driving of the trans-
ducer in the study machine. The tumor margin could
not be well identified automatically by the machine
because of insufficient contrast between the normal
and abnormal interface. As reproducibility of tumor
margin definition was very important, the tumor mar-
gin was therefore drawn manually by the operator and
then reconstructed by the US machine, i.e. the mea-
sure of tumor volume was semiautomatic. Our study
showed that the reproducibility of manually drawn
tumors was very high, even accounting for differences
between experienced sonographers, which allowed for
the easy definition of tumor margins.
The current study showed that the average tumor
volume was larger in malignant tumors than in benign
tumors, but this result did not reach statistical signifi-
cance. However, our previous larger-size study with
more patients had already confirmed these results.23
There was a large variation of tumor volume in this
study, with almost more than a 50-fold difference from
small to large tumors. Our previous report24 showed
that 2D-CDUS and 3D-PDUS were not significant
indicators for differentiation of soft-tissue tumors.
Therefore, the volume effect was not a significant factor
for influencing outcome. VI, FI and VFI were mea-
sured in the whole volume of the tumor in this study,
and we found that there was no significant difference
between benign and malignant soft-tissue tumors.
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Table 1. VI, FI and VFI in benign and malignant tumors without
contrast medium*
VI (%) FI VFI
Benign 3.22 ± 2.04 32.26 ± 5.51 1.07 ± 0.65
(0.02−5.48) (20.24−38.78) (0.004−1.82)
Malignant 1.97 ± 3.29 29.33 ± 4.86 0.67 ± 1.13 
(0.04−12.12) (21.59−38.02) (0.01−1.52)
T −0.333 −0.160 −0.128
p NS NS NS
*Data presented as mean ± standard deviation (range). VI = vascular index; FI =
flow index; VFI = vascular-flow index; T = according to the results of a t test;
NS = not significant.
Figure 1. A 63-year-old male patient with the complaint of a right
thigh mass. (A) 3D power Doppler ultrasonography shows an
ovoid-shaped hypoechoic nodule with mild vascularity (VI, 2.5%;
FI, 36; VFI, 0.9). (B) 3D power Doppler ultrasonography shows an
ovoid-shaped hypoechoic nodule with mild vascularity (VI, 2.5%; FI,
36; VFI, 0.9). (C) After contrast injection, 3D power Doppler ultra-
sonography shows relatively increased vascularity (VI, 6.6%; FI,




The standard deviation values for VI and VFI were
very high compared with the mean values in benign
and malignant tumors. One possibility for this finding
could be that there was a very large variety in the range
of VI and VFI in soft-tissue neoplasms. Therefore, there
was no statistically significant difference between benign
and malignant soft-tissue tumors as evaluated by 3D-
PDUS, which is consistent with our previous study.23
There were no significant differences in volume,
VI, FI, and VFI before contrast injection in this study
between benign and malignant tumors, which is simi-
lar to the findings of our previous study.22 In fact, this
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Figure 2. A 43-year-old female patient with the complaint of a pal-
pable mass in her right thigh for 2 years. (A) Grayscale ultra-
sonography shows an ovoid-shaped heterogeneous echoic nodule
(dotted lines) over the right thigh. (B) 3D power Doppler ultra-
sonography shows only minimal vascularity within the tumor (VI,
0.5%; FI, 26.1; VFI, 0.14). (C) After contrast injection, 3D power
Doppler ultrasonography shows marked hypervascularity (VI,
32.9%; FI, 32.6; VFI, 10.7). This tumor was a liposarcoma.
Table 2. VI, FI and VFI in benign and malignant tumors after 
contrast medium injection*
VI (%) FI VFI
Benign 20.85 ± 22.45 37.33 ± 5.32 8.52 ± 10.06 
(0.14−64.32) (17.63−44.63) (0.03−28.7)
Malignant 40.12 ± 24.39 41.21 ± 7.81 17.77 ± 14.91 
(3.04−95.64) (32.64−48.59) (1.19−40.71)
T −1.889 −1.722 −1.834
p NS NS NS
*Data presented as mean ± standard deviation (range). VI = vascular index; FI =
flow index; VFI = vascular-flow index; T = according to the results of a t test;










Figure 3. The correlation between the 2 sonographers’ tracing of
18 soft-tissue tumors.
Table 3. Difference in VI, FI and VFI (after minus before contrast
medium injection) in benign and malignant tumors*
VI (%) FI VFI
Benign 17.63 ± 20.98 5.07 ± 4.58 7.45 ± 9.58
Malignant 38.15 ± 22.55 11.88 ± 6.67 16.55 ± 14.1
T −2.167 −2.556 −2.167
p 0.03 0.01 0.03
*Data presented as mean ± standard deviation. VI = vascular index; FI = flow
index; VFI = vascular-flow index; T = according to the results of a t test.
phenomenon is similar to results obtained with 2D-
CDUS, in which tumor vascularity grading could not
be reduced to a single parameter to differentiate be-
tween benign and malignant tumors.10,11 Some studies
have also shown high vessel density in hemangioma.25,26
Since volume data were acquired from the accumu-
lation of 12 slices of CDUS images in this study, the
information should be similar to isolated CDUS images.
CDUS application in soft-tissue tumors has been
discussed in many reports that analyzed the sonomor-
phology of tumor vessels or the flow velocity and resis-
tive index of tumor vessels, with variable results.27,28
The presence of tumor vessels within the tumor does
not provide sufficient information for a differential
diagnosis of benign or malignant soft-tissue tumors;
therefore, we added another parameter, echo-contrast
enhancement grading. Grading (the difference between
with and without contrast) of contrast enhancement was
significantly different between benign and malignant
tumors in this study. Malignant tumors showed more
tumor vessels and a higher VI, FI and VFI after contrast
medium injection compared with benign tumors.
We found that US with contrast images was
markedly better than non-contrast images at detecting
vessels in most tumors, although benign and malignant
tumors showed no significant difference in VI, FI and
VFI. Detailed data analysis showed a large-scale distri-
bution of contrast enhancement in both benign and
malignant tumors, which resulted in no statistical dif-
ference. Although malignant neoplasms need sufficient
tumor vessels to supply nutrition, our study showed
that vascularity was not higher in malignant soft-tissue
tumors, which may be due to tumor necrosis resulting
in tumor vessel destruction or reduced tumor size.29
However, the number of tumors was limited in this
study, and a larger study will be needed to draw firm
conclusions.
In conclusion, 3D-PDUS is a valuable tool in the
differential diagnosis of soft-tissue tumors, especially
with injection of echo-contrast medium.
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